| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | Amino acids R40-R298 from the human protein were used as the immunogen for the SPRED2 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
SPRED2 Antibody / Sprouty-related EVH1 domain-containing protein 2 is a anti-SPRED2 Rabbit antibody Polyclonal (rabbit origin) supplied in Antigen affinity purified format. Recommended for workflows such as Western blot (WB), IHC-P, Immunofluorescence (IF), Flow cytometry (FACS), ELISA with listed reactivity in Human, Mouse, Rat. Reported localization: Cytoplasm, nucleus.
Key elements and design rationale
- Target: SPRED2
- Antibody details: Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG
- Format: Antigen affinity purified
- Applications (as listed): WB, IHC-P, IF, FACS, ELISA
Biological background
SPRED2 contains an N-terminal Ena/VASP homology 1 (EVH1) domain, a central c-Kit binding domain, and a C-terminal Sprouty-related cysteine-rich domain. These structural motifs allow SPRED2 to localize to the plasma membrane and recruit signaling proteins, where it inhibits Ras and Raf activation. Employing a SPRED2 antibody allows scientists to study how this protein maintains signaling balance across a variety of cell types.
Altered expression of SPRED2 has been linked to human disease. Loss or reduction of SPRED2 function has been associated with enhanced MAPK pathway activity, which may contribute to oncogenesis and abnormal tissue growth. Additionally, SPRED2 is studied in the context of immune regulation and inflammation, where dysregulated signaling can lead to pathological outcomes. Using a SPRED2 antibody supports research into these processes and offers insight into therapeutic strategies aimed at modulating Ras/MAPK signaling.
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
- Immunofluorescence: visualize subcellular distribution and cell-to-cell heterogeneity.
- Immunohistochemistry: map target signal in tissue context and compare regions/phenotypes.
- Flow cytometry: quantify target-positive populations and signal shifts at single-cell resolution.
- ELISA: support antibody-based quantification in assay formats where applicable.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Polyclonal antibodies recognize multiple epitopes, which can broaden the epitope footprint and may increase sensitivity in some contexts.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
